Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 316, 48-52
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Worldwide Prevalence of Familial HypercholesterolemiaJACC, 2020
- Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countriesAtherosclerosis, 2020
- Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of careAtherosclerosis, 2019
- 20-Year Follow-up of Statins in Children with Familial HypercholesterolemiaNew England Journal of Medicine, 2019
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean Heart Journal, 2019
- Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world?European Heart Journal, 2017
- Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217European Heart Journal, 2016
- Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatmentEuropean Heart Journal, 2015
- Update of the molecular basis of familial hypercholesterolemia in The NetherlandsHuman Mutation, 2005